Reuters logo
BRIEF-U.S. Food and Drug Administration expands approval of Sprycel (dasatinib)
2017年11月10日 / 中午11点49分 / 12 天前

BRIEF-U.S. Food and Drug Administration expands approval of Sprycel (dasatinib)

Nov 10 (Reuters) - Bristol-myers Squibb Co:

* U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) to include treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

* Approval based on data from prospective trial in pediatric chronic myeloid leukemia in chronic phase​

* Co says ‍continues to explore pediatric applications for investigational oncology agents within its broad development program​

* Approval for Sprycel granted under priority review, indication received Orphan Drug Designation from FDA Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below